COVID-19 and haemodynamic failure: a point of view on mechanisms and treatment

被引:5
作者
Jasinski, Tomasz [1 ]
Stefaniak, Jan [1 ]
机构
[1] Med Univ Gdansk, Dept Anaesthesiol & Intens Therapy, 17 Smoluchowskiego St, PL-80214 Gdansk, Poland
关键词
hemodynamics; COVID-19; critical care; SARS-CoV-2; cardiovascular; HYPOXIC PULMONARY VASOCONSTRICTION; ACUTE KIDNEY INJURY; NEW-YORK-CITY; SEPTIC SHOCK; ANGIOTENSIN-II; SEVERE SEPSIS; SYSTEMIC INFLAMMATION; MORTALITY; MANAGEMENT; OUTCOMES;
D O I
10.5114/ait.2020.101813
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The SARS-CoV-2-related disease has an undoubted impact on the healthcare system. In the treatment of severe COVID-19 cases, the main focus is on respiratory failure. However, available data suggest an important contribution of haemodynamic impairment in the course of this disease. SARS-CoV-2 may affect the circulatory system in various ways that are universal for septic conditions. Nonetheless, unique features of this pathogen, e.g. direct insult leading to myocarditis and renin-angiotensin-aldosterone axis dysregulation, must be taken into account. Although current recommendations on COVID-19 resemble previous septic shock guidelines, special attention to haemodynamic monitoring and treatment is necessary. Regarding treatment, one must take into account the potential profound hypovolaemia of severe COVID-19 patients. Pharmacological cardiovascular support should follow existing guidelines and practice. Interesting concepts of decatecholaminisation and the effect of vasopressors on pulmonary circulation are also presented in this review on COVID-19-related haemodynamic failure.
引用
收藏
页码:409 / 417
页数:9
相关论文
共 111 条
[1]   Cardioprotection, attenuated systemic inflammation, and survival benefit of β1-adrenoceptor blockade in severe sepsis in rats [J].
Ackland, Gareth L. ;
Yao, Song T. ;
Rudiger, Alain ;
Dyson, Alex ;
Stidwill, Ray ;
Poputnikov, Dmitry ;
Singer, Mervyn ;
Gourine, Alexander V. .
CRITICAL CARE MEDICINE, 2010, 38 (02) :388-394
[2]  
Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
[3]   Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum [J].
Andreis, Davide Tommaso ;
Singer, Mervyn .
INTENSIVE CARE MEDICINE, 2016, 42 (09) :1387-1397
[4]  
[Anonymous], 2020, NATURE, DOI DOI 10.1038/s41586-020-2012-7
[5]  
[Anonymous], 2020, WEEKLY EPIDEMIOLOGIC
[6]  
[Anonymous], Lancet, DOI DOI 10.1016/S0140-6736(20)30567-5
[7]  
[Anonymous], 2020, CHINA CDC WEEKLY, DOI DOI 10.46234/ccdcw2020.032
[8]   Angiotensin II in ECMO patients: a word of caution [J].
Antonucci, Elio ;
Taccone, Fabio Silvio .
CRITICAL CARE, 2019, 23 (1)
[9]  
Balik M, 2017, ANAESTH INTENSIVE TH, V49, P419, DOI 10.5603/AIT.a2017.0061
[10]   The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials [J].
Belletti, A. ;
Castro, M. L. ;
Silvetti, S. ;
Greco, T. ;
Biondi-Zoccai, G. ;
Pasin, L. ;
Zangrillo, A. ;
Landoni, G. .
BRITISH JOURNAL OF ANAESTHESIA, 2015, 115 (05) :656-675